CN114555614A - 作为非pgp底物的抗癌化合物 - Google Patents

作为非pgp底物的抗癌化合物 Download PDF

Info

Publication number
CN114555614A
CN114555614A CN202080067380.4A CN202080067380A CN114555614A CN 114555614 A CN114555614 A CN 114555614A CN 202080067380 A CN202080067380 A CN 202080067380A CN 114555614 A CN114555614 A CN 114555614A
Authority
CN
China
Prior art keywords
substituted
group
compound
aryl
heterocycle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080067380.4A
Other languages
English (en)
Inventor
段建新
李安蓉
蔡晓宏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen Ascentawits Pharmaceutical Technology Co ltd
Original Assignee
Shenzhen Ascentawits Pharmaceutical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Ascentawits Pharmaceutical Technology Co ltd filed Critical Shenzhen Ascentawits Pharmaceutical Technology Co ltd
Publication of CN114555614A publication Critical patent/CN114555614A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/564—Three-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/396—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having three-membered rings, e.g. aziridine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明提供作为非PGP底物的抗癌化合物，其为式I‑1化合物或者其药学上可接受的盐、前药或溶剂合物：

Description

PCT国内申请，说明书已公开。

Claims (29)

  1. PCT国内申请，权利要求书已公开。
CN202080067380.4A 2019-11-01 2020-10-30 作为非pgp底物的抗癌化合物 Pending CN114555614A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2019110601337 2019-11-01
CN201911060133 2019-11-01
CN2019113239085 2019-12-20
CN201911323908 2019-12-20
PCT/CN2020/125123 WO2021083310A1 (zh) 2019-11-01 2020-10-30 作为非pgp底物的抗癌化合物

Publications (1)

Publication Number Publication Date
CN114555614A true CN114555614A (zh) 2022-05-27

Family

ID=75714863

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080067380.4A Pending CN114555614A (zh) 2019-11-01 2020-10-30 作为非pgp底物的抗癌化合物

Country Status (4)

Country Link
US (1) US20220387345A1 (zh)
EP (1) EP4053135A4 (zh)
CN (1) CN114555614A (zh)
WO (1) WO2021083310A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024078568A1 (zh) * 2022-10-12 2024-04-18 深圳艾欣达伟医药科技有限公司 Akr1c3激活抗癌前药化合物与镇痛药物联用治疗伴有疼痛的癌症患者

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023077452A1 (zh) * 2021-11-05 2023-05-11 深圳艾欣达伟医药科技有限公司 Akr1c3活化的dna烷化剂及其医药用途
CN116120365A (zh) * 2021-11-12 2023-05-16 深圳艾欣达伟医药科技有限公司 一种氘代化合物及其制备方法和应用
WO2023237080A1 (zh) * 2022-06-10 2023-12-14 深圳艾欣达伟医药科技有限公司 Akr1c3酶激活前药治疗癌症患者的方法
WO2024078392A1 (en) * 2022-10-09 2024-04-18 Anrui Biomedical Technology (Guangzhou) Co., Ltd. Phosphoramidate compounds and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016061342A1 (en) 2014-10-17 2016-04-21 Albemarle Corporation Methods for quantifying zinc content of fluids
TWI674258B (zh) * 2015-03-10 2019-10-11 大陸商深圳艾欣達偉醫藥科技有限公司 Ｄｎａ烷化劑
SG10201913709QA (en) 2015-04-02 2020-03-30 Ascentawits Pharmaceuticals Ltd Nitrobenzyl derivatives of anti-cancer agents
JP7327900B2 (ja) * 2015-06-24 2023-08-16 スレッシュホールド ファーマシューティカルズ， インコーポレイテッド アジリジン含有ｄｎａアルキル化剤
CN108290911B (zh) 2015-11-16 2020-05-08 深圳艾欣达伟医药科技有限公司 (r)-及(s)-1-(3-(3-n,n-二甲基胺基羰基)苯氧基-4-硝苯基)-1-乙基-n,n’-双(伸乙基)胺基磷酸酯、组合物及其使用及制备方法
US20220119429A1 (en) * 2019-05-13 2022-04-21 Ascentawits Pharmaceuticals, Ltd. Fluorine-containing compound and anti-cancer medical use thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024078568A1 (zh) * 2022-10-12 2024-04-18 深圳艾欣达伟医药科技有限公司 Akr1c3激活抗癌前药化合物与镇痛药物联用治疗伴有疼痛的癌症患者

Also Published As

Publication number Publication date
EP4053135A4 (en) 2024-01-03
EP4053135A1 (en) 2022-09-07
WO2021083310A1 (zh) 2021-05-06
US20220387345A1 (en) 2022-12-08

Similar Documents

Publication Publication Date Title
CN114555614A (zh) 作为非pgp底物的抗癌化合物
CN113853379B (zh) 含氟化合物及抗癌医药用途
CN111902417B (zh) 一种二芳基巨环化合物、药物组合物以及其用途
CN105254615B (zh) 苯胺嘧啶衍生物及其在制备抗恶性肿瘤药物中的用途
Chen et al. Synthesis and biological evaluation of 1, 9-disubstituted β-carbolines as potent DNA intercalating and cytotoxic agents
Chen et al. Discovery of 4-anilinofuro [2, 3-b] quinoline derivatives as selective and orally active compounds against non-small-cell lung cancers
US20060270702A1 (en) Certain substituted ureas, as modulators of kinase activity
CN110194762B (zh) 酞嗪酮类衍生物、其制备方法和用途
CN110790749B (zh) 一种含氮杂环化合物、药物组合物以及其用途
Kadayat et al. Modified 2, 4-diaryl-5H-indeno [1, 2-b] pyridines with hydroxyl and chlorine moiety: synthesis, anticancer activity, and structure–activity relationship study
CN109467549B (zh) 喹啉取代查尔酮类化合物、其制备方法及用途
TW202135831A (zh) 含氟化合物、含氟化合物之製備方法及其抗癌醫藥用途
CN111303026A (zh) 一种恩诺沙星的丙烯酮衍生物及其制备方法和应用
CN107501279B (zh) 呋喃并喹啉二酮类化合物及其医药用途
Liu et al. Discovery of novel tacrine derivatives as potent antiproliferative agents with CDKs inhibitory property
WO2022007841A1 (zh) 一种egfr抑制剂、其制备方法和在药学上的应用
BR112020007924A2 (pt) derivados macrocíclicos, processo para a preparação dos mesmos e composições farmacêuticas contendo os mesmos
KR102690225B1 (ko) 퀴놀린 함유 화합물, 의약 조성물 및 그의 용도
CN111303027A (zh) 一种氟罗沙星的丙烯酮衍生物及其制备方法和应用
Rajendar et al. Synthesis and biological evolution of aryl quinolin-benzimidazole-1, 2, 3-triazole as anticancer agents
KR20230133396A (ko) Rip2 키나아제 억제제로서의 헤테로아릴 화합물, 이의 조성물 및 용도
KR20230104614A (ko) 아세트아미도-페닐벤즈아미드 유도체 및 그의 사용 방법
CN112824396A (zh) 一种n-乙酰基洛美沙星的丙烯酮衍生物及其制备方法和应用
CN111320578A (zh) 一种脱n-甲基氟罗沙星的丙烯酮衍生物及其制备方法和应用
KR20210151051A (ko) 암 치료를 위한 fgfr 억제제

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination